A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Condition(s):Metastatic Hormone-sensitive Prostate CancerLast Updated:March 27, 2024Recruiting